INS and metabolic dysfunction-associated steatotic liver disease: In fact—consistent with its design—this study cannot enable us to derive absolute and actual data for the prevalence of insulin-sensitive FCH subjects among the general population, nor for clinical or subclinical carotid atherosclerosis among insulin-sensitive FCH, or for NAFLD and hepatic fibrosis in this clinical setting.